## 3 Results
### Cohort Analysis
\begin{table}
\begin{tabular}{l c c c c c c c} \hline \hline \multicolumn{1}{c}{**Variable**} & \multicolumn{4}{c}{**Training and Validation**} & \multicolumn{4}{c}{**Testing**} \\ \hline
**Mean (STD)** & **All** & **AKI** & **Non-AKI** & \(p\)**-Value** & **AKI** & **Non-AKI** & \(p\)**-Value** \\ \hline
**Vital signs,** & 4278 & 1492 & 2382 & — & 139 & 265 & — \\
**N** & 11.4 & 129.69 & 132.41 & \(p<0.01\)** & 130.75 & 132.23 & 0.56 \\ SBP(mmHg) & (23.68) & (25.04) & (22.68) & & (26.76) & (22.48) & \\ DBP(mmHg) & 78 & 76.51 & 78.85 & \(p<0.01\)** & 76.15 & 79.59 & 0.05 \\  & (16.77) & (17.43) & (16.26) & & (18.59) & (15.79) & 0.05 \\ Pulse pressure & 53.35 & 53.18 & 53.49 & 0.62 & 54.6 & 52.42 & 0.29 \\  & (19.42) & (20.63) & (18.85) & & (23.88) & (17.72) & \\ Oximetry(\%) & 98.21 & 97.93 & 98.39 & \(p<0.01\)** & 98.09 & 98.3 & 0.53 \\  & (2.87) & (3.45) & (2.37) & & (3.51) & (2.92) & \\ Respiratory rate & 18.86 & 19.42 & 18.44 & \(p<0.01\)** & 20.54 & 18.6 & \(p<0.01\)** \\  & (3.92) & (4.36) & (3.44) & & (5.74) & (3.49) & \\ Pulse rate(/min) & 90.17 & 94.48 & 87.45 & \(p<0.01\)** & 95.22 & 87.68 & \(p<0.01\)** \\  & (19.98) & (21.12) & (18.68) & & (21.37) & (19.24) & \\ Temperature(Celsius) & 36.63 & 94.48 & 36.58 & \(p<0.01\)** & 36.76 & 36.57 & 0.05 \\
**Medication,** & (0.93) & (21.12) & (0.87) & & (1.11) & (0.82) & \\
**Vasopressin** & 24 & 13 & 7 & \(p<0.05\)* & 1 & 3 & 0.69 \\  & (0.86\%) & (0.87\%) & (0.29\%) & (0.72\%) & (1.13\%) & & \\ Nonrepinephrine & 826 & 398 & 348 & \(p<0.01\)** & 38 & 42 & \(p<0.01\)** \\  & (19.31\%) & (26.68\%) & (146.61\%) & & (27.34\%) & (15.85\%) & \\ Dopamine & 451 & 156 & 253 & 0.87 & 14 & 2 & 0.88 \\  & (10.54\%) & (10.46\%) & (10.62\%) & & (10.07\%) & (10.57\%) & \\ Epinephrine & 278 & 145 & 102 & \(p<0.01\)** & 16 & 15 & \(p<0.05\)* \\  & (6.5\%) & (9.72\%) & (4.28\%) & & (11.51\%) & (6.66\%) & \\  & 59 & 23 & 31 & 0.54 & 2 & 3 & 0.79 \\  & (1.38\%) & (1.54\%) & (1.3\%) & & (1.44\%) & (1.13\%) & \\ \hline \hline \end{tabular} \({}^{*}\): \(p<0.05\); **: \(p<0.01\).  
\end{table} 
Table 6: Cohort Analysis of Vital Signs and Medications. \begin{table}
\begin{tabular}{l c c c c c c c} \hline \hline \multicolumn{1}{c}{**Variable**} & \multicolumn{4}{c}{**Training and Validation**} & \multicolumn{4}{c}{**Testing**} \\ \hline
**Mean (STD)** & **All** & **AKI** & **Non-AKI** & \(p\)**-Value** & **AKI** & **Non-AKI** & \(p\)**-Value** \\ \hline
**Ventilatory** & 4287 & 1492 & 2382 & – & 139 & 265 & – \\
**Support** & & & & & & & \\ FIO\({}_{2}\) & 70.95 & 75.4 & 67.7 & \(p<0.01\)** & 78.62 & 65.89 & \(p<0.01\)** \\  & (25.87) & (26.07) & (25.27) & (25.3) & (24.73) & & \\ PEECPAP & 4.87 & 5.06 & 4.71 & \(p<0.01\)** & 5.09 & 4.86 & 0.24 \\  & (1.69) & (1.78) & (1.59) & & (1.72) & (1.71) & \\ PAW & 23.13 & 23.21 & 22.89 & 0.61 & 23.76 & 24.38 & 0.8 \\  & (6.73) & (6.72) & (6.63) & & (8.1) & (6.71) & \\ MAPS & 11.62 & 11.93 & 11.34 & \(p<0.05\)* & 10.97 & 11.47 & 0.47 \\  & (2.55) & (2.65) & (2.52) & & (1.47) & (2.06) & \\ TOTRR & 18.89 & 19.76 & 18.1 & \(p<0.01\)** & 19.01 & 17.71 & 0.44 \\  & (5.36) & (5.8) & (4.81) & & (5.31) & (4.74) & \\ VTEXH & 0.52 & 0.52 & 0.53 & 0.28 & 0.51 & 0.49 & 0.63 \\  & (0.11) & (0.11) & (0.11) & & (0.11) & (0.13) & \\ MVEXH & 9.57 & 9.79 & 9.38 & 0.13 & 9.72 & 9.08 & 0.44 \\  & (2.8) & (0.30) & (2.61) & & (2.7) & (2.16) & \\ \hline \hline \end{tabular} \({}^{*}\): \(p<0.05\); **: \(p<0.01\).  
\end{table} 
Table 7: Cohort Analysis of Ventilatory Support.